Cite
MLA Citation
K.E. Broekman et al.. “Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores.” Cancer treatment reviews, vol. 69, 2018, pp. 233–242. http://access.bl.uk/ark:/81055/vdc_100067809291.0x000032